GlycoMimetics (GLYC) to Release Earnings on Thursday

GlycoMimetics (NASDAQ:GLYC) will be announcing its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings data on Wednesday, March 27th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The firm had revenue of $0.01 million during the quarter. On average, analysts expect GlycoMimetics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GlycoMimetics Stock Down 3.2 %

NASDAQ:GLYC opened at $0.31 on Wednesday. The company has a market cap of $19.68 million, a PE ratio of -0.53 and a beta of 2.30. The business’s 50 day moving average is $2.42 and its two-hundred day moving average is $2.33. GlycoMimetics has a 52 week low of $0.27 and a 52 week high of $3.53.

Analyst Ratings Changes

Several brokerages recently issued reports on GLYC. HC Wainwright restated a “neutral” rating on shares of GlycoMimetics in a research note on Monday. Capital One Financial restated an “overweight” rating on shares of GlycoMimetics in a research report on Thursday, February 22nd. Finally, StockNews.com downgraded shares of GlycoMimetics from a “hold” rating to a “sell” rating in a research report on Thursday, March 14th.

About GlycoMimetics

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.